CA9 and breast cancer: The model is based on the original 4T1 breast cancer cell line and two genetically edited versions of it—one with biallelic CRISPR/Cas9‐mediated Car9 inactivation and another with constitutively expressed Car9, thus ensuring negative and positive controls for CAIX production in the model system, respectively.